Alector Presents Preclinical Data from AL009 Multi-Siglec Inhibitor Program at the Society for Immunotherapy of Cancer’s 36th Annual Meeting
12 November 2021 - 11:00PM
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology
company pioneering immuno-neurology, presented preclinical data
from its AL009 immuno-oncology program in poster at the Society for
Immunotherapy of Cancer’s 36th Annual Meeting.
AL009 is a first-in-class fusion protein engineered to block
multiple Siglecs. Siglecs (sialic acid binding immunoglobulin-like
lectins) are a family of receptors involved in immune regulation
that bind to cell surface sialic acid glycans. Siglecs are
predominantly expressed on myeloid cells and the overexpression of
Siglecs has been linked to immune suppression and evasion by tumor
cells, as well as modulating the differentiation of myeloid cells
into tumor-promoting macrophages. AL009 acts as a
checkpoint inhibitor, blocking the immunosuppressive effect of
multiple Siglecs and thereby enhancing both the innate and adaptive
immune system response to cancer. Alector is developing AL009 for
the potential treatment of solid tumor cancers and plans to
initiate a first-in-human clinical trial of AL009 in 2022.
“Siglecs play a critical role in regulating immune activity, and
our research into the role of the Siglec family of inhibitory
receptors in neurodegenerative disease led to the discovery and
optimization of AL009 for immuno-oncology. AL009 is a fusion
protein uniquely able to block multiple Siglec receptors and halt
Siglec-sialic acid-mediated immune suppression, which may be
beneficial in a number of disease states where evasion of the
immune system allows disease to progress unchecked,” said Daniel
Maslyar, M.D., Alector’s Vice President Clinical Development. “As
we compared AL009 with other immunotherapies in preclinical models,
we observe higher potency in blocking immune cell suppression and
promising anti-cancer activity alone and in combination with
anti-PDL1 in multiple tumor types, including some that have been
found resistant to other immunotherapies. We look forward to
advancing AL009 into the clinic to characterize its potential to
treat a variety of solid tumor types.”
In a poster titled “AL009, a Fusion
Protein and Multi-Siglec Inhibitor, Repolarizes Suppressive Myeloid
Cells and Potentiates Anticancer Effects,” Alector researchers
highlighted:
- AL009 led to
dose-dependent increases in immune stimulatory molecules consistent
with the repolarization of myeloid-derived suppressive cells to a
proinflammatory state
- In vitro, AL009
increased T cell function by approximately 10 to 100-fold compared
to other cancer immunotherapies
- In syngeneic tumor
models in mice that were less responsive to anti-PD-L1, treatment
with AL009 showed efficacy in reducing tumor growth both as a
single agent and in combination with anti-PD-L1
- In a murine model of
lung metastasis, AL009 combined with anti-TRP1 therapy to reduce
lung nodules
The poster is available on Alector website in the Investors
section at www.alector.com. Alector management will also be
conducting a call for analysts and investors to discussion data
presented this week for four of the company’s pipeline programs,
AL001, AL101 and AL003 being developed for the treatment of
neurodegenerative diseases and AL009.
About AL009AL009 is a first-in-class multi
Siglec inhibitor that works to enhance both the innate and adaptive
immune system response to tumors by blocking a critical glycan
checkpoint pathway that drives immune inhibition. Alector is
initially developing AL009 for the potential treatment of solid
tumors, with plans to initiate first-in-human clinical studies in
2022.
About AlectorAlector is a
clinical-stage biotechnology company pioneering immuno-neurology, a
novel therapeutic approach for the treatment of neurodegenerative
diseases. Immuno-neurology targets immune dysfunction as a root
cause of multiple pathologies that are drivers of degenerative
brain disorders. Alector has discovered and is developing a broad
portfolio of innate immune system programs, designed to
functionally repair genetic mutations that cause dysfunction of the
brain’s immune system and enable the rejuvenated immune cells to
counteract emerging brain pathologies. Alector’s immuno-neurology
product candidates are supported by biomarkers and target
genetically defined patient populations in frontotemporal dementia
and Alzheimer’s disease. This scientific approach is also the basis
for the company’s immuno-oncology programs. Alector is
headquartered in South San Francisco, California. For additional
information, please visit www.alector.com.
Forward-Looking StatementsThis press release
contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Such statements
are subject to numerous important factors, risks and uncertainties
that may cause actual events or results to differ materially from
current expectations and beliefs, including but not limited to
risks and uncertainties related to market conditions, Alector and
its business as set forth in our Quarterly Report on Form 10-Q, as
filed on November 4, 2021 with the Securities and Exchange
Commission (“SEC”), as well as the other documents Alector files
from time to time with the SEC. These documents contain and
identify important factors that could cause the actual results for
Alector to differ materially from those contained in Alector’s
forward-looking statements. Any forward-looking statements
contained in this press release speak only as of the date hereof,
and Alector specifically disclaims any obligation to update any
forward-looking statement, except as required by law.
Alector ContactsMichelle CorralVP,
Communications and Investor
Relations650-808-7016michelle.corral@alector.com
1AB (media)Dan Budwick973-271-6085dan@1abmedia.com
Argot Partners (investors)Laura Perry/Eric KasperArgot
Partners212-600-1902alector@argotpartners.com
Alector (NASDAQ:ALEC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Alector (NASDAQ:ALEC)
Historical Stock Chart
From Apr 2023 to Apr 2024